Omeros (NASDAQ:OMER) Receives Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Omeros (NASDAQ:OMER) in a research report report published on Friday,Benzinga reports. They currently have a $36.00 price target on the biopharmaceutical company’s stock.

A number of other research analysts have also recently commented on OMER. HC Wainwright upped their price target on Omeros from $9.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, October 15th. Needham & Company LLC restated a “hold” rating on shares of Omeros in a report on Wednesday, October 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a report on Wednesday, October 8th. WBB Securities restated a “strong-buy” rating and issued a $45.00 price target on shares of Omeros in a research note on Wednesday, October 15th. Finally, Wall Street Zen upgraded Omeros from a “sell” rating to a “hold” rating in a research note on Saturday, September 20th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $33.67.

Omeros Stock Performance

NASDAQ:OMER opened at $7.87 on Friday. Omeros has a fifty-two week low of $2.95 and a fifty-two week high of $13.60. The company’s 50-day simple moving average is $5.78 and its 200-day simple moving average is $4.59. The stock has a market capitalization of $535.60 million, a P/E ratio of -3.73 and a beta of 2.40.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.39. On average, research analysts forecast that Omeros will post -3.09 EPS for the current year.

Hedge Funds Weigh In On Omeros

Several hedge funds have recently added to or reduced their stakes in the stock. Corton Capital Inc. purchased a new position in shares of Omeros during the second quarter worth about $117,000. Hsbc Holdings PLC purchased a new stake in Omeros in the first quarter valued at approximately $142,000. Nuveen LLC acquired a new stake in shares of Omeros in the first quarter valued at approximately $938,000. Wellington Management Group LLP purchased a new position in shares of Omeros during the first quarter worth approximately $1,118,000. Finally, Invesco Ltd. increased its holdings in shares of Omeros by 169.1% in the 1st quarter. Invesco Ltd. now owns 87,044 shares of the biopharmaceutical company’s stock valued at $716,000 after acquiring an additional 54,696 shares during the period. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.